SELLAS Life Sciences (SLS) Cost of Revenue (2013 - 2022)
SELLAS Life Sciences (SLS) reported Cost of Revenue of $100000.0 for Q1 2022, little changed year-over-year from $100000.0 in Q1 2021, and little changed on a QoQ basis from $100000.0 in Q2 2021.
SELLAS Life Sciences (SLS) has 5 years of Cost of Revenue data on file, last reported at $100000.0 in Q1 2022.
- Quarterly Cost of Revenue changed 0.0% year-over-year to $100000.0 in Q1 2022, while the trailing twelve-month figure through Dec 2022 was $100000.0 (down 50.0% YoY) and the FY2022 annual result came in at $100000.0, down 50.0% from the prior year.
- Cost of Revenue was little changed at $100000.0 in Q1 2022 per SLS's latest filing, from $100000.0 in the prior quarter.
- Across five years, Cost of Revenue topped out at $100000.0 in Q1 2021 and bottomed at $100000.0 in Q1 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 64.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 392.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 296.00 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 207.52 Mn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 100,000.00 |
| Mar 31, 2022 | 100,000.00 |
| Jun 30, 2021 | 100,000.00 |
| Jun 30, 2021 | 100,000.00 |
| Mar 31, 2021 | 100,000.00 |
| Mar 31, 2021 | 100,000.00 |
| Jun 30, 2015 | 468,000.00 |
| Jun 30, 2015 | 468,000.00 |
| Mar 31, 2015 | 393,000.00 |
| Mar 31, 2015 | 393,000.00 |
| Dec 31, 2014 | 478,000.00 |
| Dec 31, 2014 | 478,000.00 |
| Sep 30, 2014 | 247,000.00 |
| Sep 30, 2014 | 247,000.00 |
| Jun 30, 2014 | 347,000.00 |
| Jun 30, 2014 | 347,000.00 |
| Mar 31, 2014 | 331,000.00 |
| Mar 31, 2014 | 331,000.00 |
| Dec 31, 2013 | 262,000.00 |
| Dec 31, 2013 | 262,000.00 |
| Sep 30, 2013 | 258,000.00 |
| Sep 30, 2013 | 258,000.00 |